Fundraising Fox
/Companies
Sign in

Rondo Therapeutics

Founded 2021 · 29 employees on LinkedIn · 6 known investors

Find your way into Rondo Therapeutics

Sign up to see every warm intro you have to Rondo Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Rondo Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue. Its therapies aim to expand the therapeutic window for eradicating tumors.

BiotechHealthtech

Founders & leadership

Rondo Therapeutics was founded in 2021 by Shelley Force Aldred and Nathan Trinklein.

SFShelley Force Aldred
Shelley Force AldredCo-Founder & Chief Executive OfficerShelley Force Aldred earned a Ph.D. in Genetics from Stanford University and has co-founded multiple biopharmaceutical companies; she currently leads Rondo Therapeutics as CEO, guiding the company through early clinical development of bispecific antibody therapeutics for oncology.
NTNathan Trinklein
Nathan TrinkleinCo-Founder, President & CSONathan Trinklein holds a Ph.D. from Stanford University and has founded multiple biotech companies. He is co-founder, president, and chief scientific officer of Rondo Therapeutics, which develops bispecific and multispecific antibody therapeutics for immuno-oncology.
K
KatherineChief Development Officer
T
ThomasChief Medical Officer

Investors · 6

Dementia Discovery Fundlisted by Dementia Discovery FundLondon

How we know: Dementia Discovery Fund's portfolio page · Not right? Tell us

Red Tree Venturelisted by Red Tree VentureSan Diego

How we know: Red Tree Venture's portfolio page · a partner's Signal profile · Not right? Tell us

SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20M

How we know: SV Health Investors's portfolio page · prnewswire.com · Not right? Tell us

Johnson & Johnson Innovation – JJDCreportedNew Brunswick

How we know: prnewswire.com · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: prnewswire.com · Not right? Tell us

Funding

SEC filings, press & company announcements

$67M disclosed across 1 round · 2022

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumorsprnewswire.com · Mar 2022

Frequently asked questions

What does Rondo Therapeutics do?
Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue. Its therapies aim to expand the therapeutic window for eradicating tumors.
Who founded Rondo Therapeutics?
Rondo Therapeutics was founded by Shelley Force Aldred, Nathan Trinklein in 2021.
Who are Rondo Therapeutics's investors?
Rondo Therapeutics's investors include Canaan Partners, Dementia Discovery Fund, Red Tree Venture, SV Health Investors, Johnson & Johnson Innovation – JJDC, Novo Holdings.
How much funding has Rondo Therapeutics raised?
Rondo Therapeutics has disclosed $67M raised across 1 round.